1-es típusú cukorbetegség: vizsgálatok itt: Olaszország
30 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 12.. Ask the study team whether a trial fits you.
- No phaseTaking peopleReal-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)
- Where
- Ancona, Palermo, Verona
- People
- 60 worldwide
- Run by
- Sanofi
See details and how to joinNCT07457580 - 3. fázisTaking peopleA Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
- Where
- Ancona, Bologna, Cagliari, Florence, Milan, Naples, Novara, Padova, Verona
- Életkor
- 1 év to 35 év
- People
- 150 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07222137 · EU 2025-521797-34-00 - 3. fázisTaking peopleA Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
- Where
- Ancona, Florence, Messina, Milan, Naples, Novara, Padova, Verona
- Életkor
- 1 év to 35 év
- People
- 300 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07222332 · EU 2025-522170-36-00 - No phaseTaking peopleDifferentiating Heart Disease Between Adult-onset Autoimmune and Type 2 Diabetes
- Where
- Rome
- Életkor
- 30 év and over
- People
- 200
- Run by
- University of Roma La Sapienza
See details and how to joinNCT07911007 - 3. fázisTaking peopleA Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Where
- Bologna, Milan, Palermo, Pisa, Rome, Rozzano, Sesto San Giovanni, Turin
- Életkor
- 18 év and over
- People
- 2500 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07784725 · EU 2025-523379-41-00 - 4. fázisTaking peopleAnti-viral action against Type 1 diabetes autoimmunity GPPAD-05-AVAnT1A
- Where
- Milan
- Életkor
- Up to 17 év
- People
- 2365 worldwide
- Run by
- Klinikum rechts der Isar der TU Muenchen AöR
See details and how to join2023-507348-35-00 · EU 2023-507348-35-00 - 3. fázisTaking peopleA Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
- Where
- Bologna, Florence, Genoa, Messina, Milan, Novara, Pescara, Rome, Siena, Turin, Verona
- Életkor
- 1 év to 25 év
- People
- 723 worldwide
- Run by
- Sanofi
See details and how to joinNCT07088068 - 2. fázisTaking peopleSAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
- Where
- Milan, Novara, Verona
- Életkor
- 5 év to 40 év
- People
- 159 worldwide
- Run by
- SAb Biotherapeutics, Inc.
See details and how to joinNCT07187531 · EU 2025-521560-36-00 - No phaseTaking peopleStrategy For Assessing The Risk Of Type 1 Diabetes In Pediatric Celiac Patients
- Where
- Bari
- Életkor
- 1 év to 18 év
- People
- 600
- Run by
- University of Bari
See details and how to joinNCT07862101 - 3. fázisTaking peopleA Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
- Where
- Ancona, Bologna, Brescia, Catanzaro, Genoa, Messina, Milan, Perugia, Pisa
- Életkor
- 18 év and over
- People
- 2500 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07564414 · EU 2025-522488-14-00 - 3. fázisTaking peopleA trial to learn how safe elecoglipron is and how well it works in adults living with obesity or excess body weight with or without type 2 diabetes
- Where
- Bologna, Catania, Chieti, Florence, Latina, Milan, Pisa, Ravenna, Rome, San Donato Milanese
- Életkor
- 18 év and over
- People
- 1010 worldwide
- Run by
- AstraZeneca AB
See details and how to join2025-524688-19-00 · EU 2025-524688-19-00 - 3. fázisTaking peopleA Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes
- Where
- Milan
- Életkor
- 18 év to 65 év
- People
- 57 worldwide
- Run by
- Vertex Pharmaceuticals Incorporated
See details and how to joinNCT04786262 · EU 2024-513929-23-00 - 3. fázisTaking peopleAMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
- Where
- Catanzaro, Chiavari, Chieti, Lucca, Milan, Naples, Ravenna, Roma
- Életkor
- 45 év and over
- People
- 1778 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07797335 - No phaseTaking peopleINNODIA Family & Friends Early-Stage T1D Detection Protocol
- Where
- Milan
- Életkor
- 1 év to 45 év
- People
- 30 000 worldwide
- Run by
- INNODIA iVZW
See details and how to joinNCT07118098 - No phaseNot yet taking people in OlaszországTargeting GLUT1 to Control Autoimmunity in Type 1 Diabetes
- Where
- Milan
- Életkor
- 18 év and over
- People
- 84
- Run by
- IRCCS San Raffaele
See details and how to joinNCT07695727 - No phaseNot yet taking people in OlaszországM1no-Study - Early Identification of Infants With High Type 1 Diabetes Risk for Participation in Primary Prevention Trials
- Where
- Lecco, Milan, Novara, Varese
- Életkor
- 0 hét to 6 hét
- People
- 50 000
- Run by
- IRCCS San Raffaele
See details and how to joinNCT07670143 - No phaseNot yet taking people in OlaszországEvaluation of the Safety and Effectiveness of the Novel Medtronic Experimental Automated Insulin Delivery System (NMX8) in Adults Living With Type 1 Diabetes
- Where
- Bologna, Milan, Naples, Roma
- Életkor
- 18 év and over
- People
- 230 worldwide
- Run by
- Medtronic MiniMed, Inc.
See details and how to joinNCT07401901 - No phaseNot yet taking people in OlaszországStandardized Italian netwoRk Enrolling iNdividuals With Islet-Autoantibodies
- Where
- Ancona, Bari, Bolzano, Caserta, Catanzaro, Crotone, Florence, L’Aquila, Milan, Naples, Novara, Padova, Palermo, Parma, Pavia, Reggio Calabria, Roma, San Giovanni Rotondo, Taranto, Trento, Treviso, Trieste, Verona, Viterbo
- People
- 300
- Run by
- Società Italiana di Endocrinologia e Diabetologia Pediatrica
See details and how to joinNCT07503366 - No phaseTaking peopleEvaluation of Oxidative Stress: Comparison Between Type 1 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults
- Where
- Pavia
- Életkor
- 18 év to 75 év
- People
- 75
- Run by
- Fondazione IRCCS Policlinico San Matteo di Pavia
See details and how to joinNCT07434154 - No phaseTaking peopleVey Low-Energy Ketogenic Therapy in Adults With Type 1 Diabetes and Obesity on Intensive Insulin Therapy Using Advanded Hybrid Closed Loop System
- Where
- Bari
- Életkor
- 18 év to 99 év
- People
- 14
- Run by
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
See details and how to joinNCT07185555 - No phaseTaking peopleEvaluation of Main Determinants of Postprandial Glucose Response in Type 1 Diabetes
- Where
- Naples
- Életkor
- 18 év to 70 év
- People
- 200
- Run by
- Federico II University
See details and how to joinNCT05936242 - No phaseTaking peopleTrialNet Pathway to Prevention of T1D
- Where
- Milan
- Életkor
- 2 év to 45 év
- People
- 75 000 worldwide
- Run by
- University of South Florida
See details and how to joinNCT00097292 - No phaseTaking peopleReal-world Study on the Effectiveness and Safety of Control-IQ Technology in Teenagers With Type 1 Diabetes Engaging in Regular Physical Activity
- Where
- Messina
- Életkor
- Up to 20 év
- People
- 50
- Run by
- Bruno Bombaci
See details and how to joinNCT06876207 - No phaseTaking peopleGlycemic Response to Carbob-Enriched Pasta in Healthy and With Type 1 Diabetes People
- Where
- Naples
- Életkor
- 18 év to 50 év
- People
- 10
- Run by
- Federico II University
See details and how to joinNCT06994403 - 1/2. fázisNot yet taking people in OlaszországA First-in-human Clinical Trial Using a Gene Therapy With Patient's Own Stem Cells to Treat Early Type 1 Diabetes
- Where
- Padova
- Életkor
- 18 év to 40 év
- People
- 15
- Run by
- Altheia Science
See details and how to joinNCT06938334 · EU 2025-521304-21-00